To Get Full Access :

Filspari

Filspari is an oral dual endothelin and angiotensin receptor blocker approved to reduce proteinuria and slow kidney function decline in adults with IgA nephropathy.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Sparsentan
  • Innovator :

    TRAVERE THERAPEUTICS
  • Approval Date :

    17-Feb-23
  • NCE-1 Date :

    17-Feb-27
  • NCE Date :

    17-Feb-28
  • Dosage Form :

    Tablet
  • Strength :

    200 mg and 400 mg
  • Therapeutic Category :

    Antiproteinuric
  • Revenue ($M) :

    132

Year-wise Projected Sales ($M) :

  • 2025 :

    295
  • 2026 :

    434
  • 2027 :

    643
  • 2028 :

    810
  • 2029 :

    993
  • 2030 :

    1,189
  • 2031 :

    1,386
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?